ranchhand71 Thursday, 05/13/21 10:17:16 AM Re: None Post # of 26389 Recent Maxim analyst report with $14 12 month target price. 2021 Revenues Est $50,299,000 2022 Revenues Est $70,000,000 Also show revenues greater than expenses for first time in Q1 2022! Other comments: CytoSorbents reported 1Q21 results on 5/4, post-close with product sales of $10.6M, down 12% from 4Q20 and up 24% y/y. The company reported a net loss of ($0.4M) and ended the period with $68.5M in cash on the balance sheet. • The pullback was based on COVID restrictions in Europe, combined with a trough in cases reducing COVID sales. That said, the overall base business performed well vs. prior quarters. • Clinical programs are making progress. REFRESH 2-AKI has resumed enrollment and data is expected from the CTC Registry study of CytoSorb inCOVID-19 and the REMOVE endocarditis study in mid-2020. The CYTATION Study has also begun enrolling patients in Germany. • Conclusion. Over 2021, we expect COVID-19 revenues to continue to support topline. As lockdown restrictions ease, CytoSorbents should be able to fullyleverage its approval in removal of blood thinners to drive growth in its base business.